MDLN Medline sharp Q4 2025 EPS miss triggers investor selloff pushing shares down 318 today Regeneron Pharmaceuticals REGN Otarmeni Gene Therapy Launch Shifts LongTerm Narrative Amid Pipeline Execution Focus USGOW US quarterly earnings metrics are not yet available with investors awaiting fresh operational updates